Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
SEATTLE, April 09, 2018 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2018 financial results after the close of trading on Tuesday, May 8, 2018. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 6188428. To listen to a live webcast, please visit the investor relations section of the company’s website at nanostring.com.
A replay of the call will be available beginning May 8, 2018 at 7:30pm ET through midnight on May 15, 2018. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 6188428. The webcast will also be available on the Company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
[email protected]
Phone: 206-602-1768
